Heidelberg Pharma : Aktuelle Unternehmenspräsentation, Mai 2024

ATACs: Unique new mode of action to fight cancer

May 2024

Safe harbor

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.

ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.

© Heidelberg Pharma AG

2

Management team with strong pharma and R&D experience

Prof. Dr. Andreas Pahl

CEO

Heidelberg Pharma since 2012, CEO since 2024

Professor of Pharmacology and Toxicology at the University of Erlangen- Nuremberg (FAU) with 25 years experience in research and higher education

Walter Miller

CFO

Heidelberg Pharma since 2023

More than 20 years of experience in corporate finance, M&A, strategic controlling, accounting and corporate development

Dr. András Strassz

CMO

Heidelberg Pharma since 2020

More than 15 years experience in clinical drug development including roles at Sandoz, Amgen and biotech companies

Dr. George Badescu

CBO

Heidelberg Pharma since 2018

More than 15 years experience in industry roles including leadership positions at Abzena

Dr. Jörg Kemkowski

COO

Heidelberg Pharma since 2023

More than 30 years experience in human and animal healthcare industry in different R&D leadership positions

© Heidelberg Pharma AG

3

Building a world class ADC pipeline

Differentiated ADC Technologies

• In Plug & Play mode
• 3 years from target to IND

GMP Manufacturing

• Fully synthetic process for Amanitin
• 5 GMP batches completed

Clinical Stage

• Data from HDP-101 dose escalation shows first objective responses and partial remissions
• HDP-102CTA & FPI this year
• 2 additional CTAs in preparation

© Heidelberg Pharma AG

Strong IP

• Several IP families
• Monopoly in the Amanitin/MoA space

Partnerships

• Huadong: China-focused
• Takeda: ATAC technology
• Healthcare Royalty: Telix Pharma

Corporate & Finance

• Experienced leadership team; 105 employees
• Cash (runway): €32.6 million* (mid-2025)
• 75m USD milestone payment expected end of 2024
• • as per end of February 2024

4

Strong in-house R&D capabilities and expertise

Synthetic chemistry	Antibody generation	Preclinical testing
					& bioconjugation

CMC

Bioanalytical sciences

Clinical Development

Best ADC candidate in the shortest time

© Heidelberg Pharma AG

5

Value creation through development of best-in-class ADC assets

Discovery & development engine

Scouting

Partnering

In-licensing

We are NOT a Target ID Company

Toolbox

of proprietary

payloads

Multiple targets

Development

AntibodiesExpertise

Partnering at IND-ready, First clinical data, EOP1, Clinical POC

Co-Development

Upside: Retain territorial rights for potential commercialization

© Heidelberg Pharma AG

6

Payload Toolbox - Multiple MOAs

Developing an ADC toolbox and clinical product pipeline to overcome tumor resistance across cancer types

Toolbox

of proprietary

payloads

ATAC Technology

RNA-Polymerase II Inhibitor

Amanitin based

TOPO I Technology

Topoisomerase I Inhibitor

Exatecan based

Immune-modulation

Technology

TLR7 agonist

Different payloads and antibodies will lead to multiple development candidates with different modes of actions

© Heidelberg Pharma AG	7

Growing pipeline of proprietary and partnered programs

	Product	Target	Indication	Research Preclinic Phase I Phase II	Phase III Partner
	HDP-101	BCMA	Multiple Myeloma						Huadong (China+*)
pipeline
HDP-102	CD37	NHL (DLBCL/CLL)						Huadong (option China+)
ATAC
HDP-103	PSMA	Prostate cancer						Huadong (China+)
	HDP-104	GCC	Gastrointestinal (e.g., CRC)						Huadong (option China+)
TOPO	HDP-201	GCC	Gastrointestinal						Proprietary
ATAC partners	TAK-ATAC	n/a	Oncology						Takeda
assets	TLX250-CDx	CA-IX	Renal Carcinoma						Telix
Urothelial Carcinoma, TNBC
Legacy
TLX250	CA-IX	Renal carcinoma						Telix
	RHB-107		Oncology/GI, Covid-19						RedHill

• People's Republic of China, Hong Kong, Macao, Taiwan, South Korea, Indonesia, Singapore, The Philippines, Thailand, Bangladesh, Bhutan, Brunei, Myanmar, Cambodia, Laos, Malaysia, Maldives, Mongolia, Nepal and Vietnam; excludes Japan, India, Pakistan, Sri Lanka

© Heidelberg Pharma AG

8

Resistance is one of the biggest challenges in oncology

1 in 2	> 90%
people will be diagnosed	of cancer deaths
with cancer in their	are caused by drug
lifetime	resistance

© Heidelberg Pharma AG

9

The journey of many cancer patients

Before Treatment

Treatment

Resistance & Relapse

Wagke, N.et al, J Clin Oncol. 2011; 29(22): 3085-3096

We need new drugs with new mode-of-action to overcome resistance

© Heidelberg Pharma AG

10